Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Galileo Biosystems Inc. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner, which indicates a concentrated prosecution focus. The involvement of 1 distinct art unit further suggests that the company's current patent activity is confined to a specific technical niche within the USPTO.
The busiest examiner for this portfolio is OTTON, ALICIA L, who is responsible for 1 pending office action. As there is only 1 pending action in total, OTTON, ALICIA L handles the entirety of the company's current pending workload. This one-to-one relationship between the examiner and the portfolio's pending matters simplifies the prosecution landscape.
Practitioners should focus on the specific examination style of the 1 distinct examiner and the standards of the 1 distinct art unit. Because the Biotechnology & Pharmaceuticals area is the sole technology area represented, the company's current legal efforts are technically unified. The presence of only 1 pending office action means that the company's immediate success in this area depends entirely on the outcome of this single proceeding.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OTTON, ALICIA L | 1 | 65.0% | +9.3% |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18700236 | ARYL HYDROCARBON RECEPTOR (AHR) MODULATORS AND THERAPEUTIC USES THEREOF | OTTON, ALICIA L | 1699 | §112 | Non-Final OA | — | Pending | Apr 10, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGalileo Biosystems Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alicia L Otton has the most, with 1 of Galileo Biosystems Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
